Advertisement
Advertisement
U.S. Markets close in 2 hrs 7 mins
Advertisement
Advertisement
Advertisement
Advertisement

aTyr Pharma, Inc. (LIFE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8500+0.1000 (+3.64%)
As of 01:50PM EDT. Market open.
Advertisement
Sign in to post a message.
  • R
    Richard
    Look at DTIL tonight, made a big deal with Novartis....LIFE with do a deal with big pharmy soon, just wait.
  • g
    gayle siebern
    missed the rest: repeat: Piper Sandler Adjusts ATyr Pharma's Price Target to $11 From $19, Reiterates Overweight Rating
  • g
    gayle siebern
    Piper Sandler cuts target price to $11 from $19.
  • A
    Arcadia
    LIFE
    According to a post on the FDA's website, aTyr Pharma' efzofitimod was granted FDA orphan designation in the treatment of Systemic Sclerosis. Reported on 04/12/2022.
  • S
    Shlomo
    (LIFE) Market Cap 34 million / Cash Balance 42 million / Phase 2 readout of the Covid 19 treatment imminent (during this Quarter) , Only 10 million outstanding shares = This low float stock could hit $10++ very fast on positive results = STRONG BUY

    "The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.

    Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.

    This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”

    If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”

    Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”

    Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target. "
    https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html
    The dog days of summer have come to a close, and investors want to know what the fall has in store for the market. August was kind to the stock market, with the S&P 500 gaining more than 7% in the month. This impressive performance marked the index’s
    The dog days of summer have come to a close, and investors want to know what the fall has in store for the market. August was kind to the stock market, with the S&P 500 gaining more than 7% in the month. This impressive performance marked the index’s
    finance.yahoo.com
  • E
    Edward
    $LIFE just out with positive trial news: “Against the backdrop of the rapidly evolving standard of care for COVID-19 patients, we have reaffirmed the positive safety profile of ATYR1923 observed in our ongoing trial in patients with pulmonary sarcoidosis, a chronic form of inflammatory lung disease. We have also elucidated a signal of drug activity from a single 3.0 mg/kg dose of ATYR9123 in this small trial. I would like to thank the clinical sites, investigators and patients that contributed to these important findings,” said Dr. Shukla.
  • V
    Venkatesan
    The market has been bad until today it decided to surge. Everybody was practically crying then. It kept dipping. That's what you get when you feel you can navigate the process on your own. Big thanks to EXPERT Jackson Eric . I'm not bothered with how bad the market is because my assets are insured due to his advice and I still receive my huge profits
  • s
    sea
    aTyr Pharma initiated with a Buy at Roth Capital Roth Capital analyst Zegbeh Jallah initiated coverage of aTyr Pharma with a Buy rating and $15 price target. NOW UPPED TO "=
    20...The analyst cited "strong" scientific data for the company's lead candidate, ATYR1923, a tRNA synthetase-derived drug for Pulmonary Sarcoidosis an interstitial lung disease for which efficacy data is expected during Q3; '1923's potential to capture share in the larger ILD market; and collaborations with CSL-Behring and Kyorin that provide further platform validation and non-dilutive capital...
  • J
    JamesA
    The data collected near the end of the ongoing clinical study could provide insight on whether ATYR1923 limits the amount of permanent scarring of the lungs (pulmonary fibrosis), verses the current standard of care (dexamethasone and remdesivir) for treating covid-19. Given those treated with ATYR1923 left the hospital sooner, we very well may see some benefit.
  • A
    Anonymous
    director cofounder bought 250,000 shares in the offering- Dr Schimmel
    Bullish
  • d
    dearie
    Setting good entry targets, and understanding market psychology, Recognizing and applying risk spectrums around different options trading strategies, Putting it all together – PLUS, Jeff reveals his favorite trading setups and his actual top trading idea of the entire week. Don't miss this zero cost live option training series with JEFF BISHOP! https://dailytrading.tools/ay8t4d
  • J
    JamesA
    An analyst encouraged the CEO to discuss emergency use with the FDA, as they had minimal side effects and significant activity to lower patient hospitalizations to less than 6 days. The analysts were positive. But this study was small, so the FDA might require another study with more patients, that could take 9 more months and more funding. The CEO agreed it was promising, but didn't say much more about that.
  • K
    Kenneth
    NEWS:
    Two papers recently published in
    @ScienceMagazine
    note that the SARS-CoV-2 virus is able to enter cells via neuropilin receptors, including neuropilin-2 (NRP2), the target receptor of ATYR1923
  • s
    sea
    Of RNA stocks this one is the most overlooked? being tRNA. Atyr is working on a many patented tRNA protein families... but since Nature: ...There is an incalculable number of potential molecular tRNA species, represented by their post-transcriptionally modified forms, by the presence of isoacceptors and isodecoders as well as by the generation of tRNA fragments and the formation of complexes between tRNAs and various proteins.... not all tRNA!
    But still, Atyr is only listed co. saying it is working on tRNA?
    This was a safety trial... results were as clean as you can get... unusual. Don't often hear Outstanding and Dramatic so often to describe clinical results. And a really long cc for a sub 100 m stock. They need cash to go forward, hopefully they price a deal at 20-50... or more....
    Market cap yesterday was back where it was before they focussed on this 1923 and the stock crashed. IF they can show in a P3 what they did in the P2, then the co is in a position like Fibrogen with a 6B valuation, before it in turn crashed. a 30x difference to today.... time will tell, about 2-3 years needed...
    SA ha some great articles on Atyr which make great hindsight reading.
  • S
    Steve
    As my average share acquisition price was $64.90 a share, you can imagine my lack of excitement over this latest price move.

    It just needs to go up 10X to get to price levels before the 1:10 reverse split. LOL
  • m
    mathew
    👍👍Analyst Joseph Pantginis from RC Wainwright notes that there are currently no drugs approved for pulmonary sarcoidosis, believes the "broad set of positive data and trends in the efficacy endpoints provide solid footings" for planned FDA meeting. Price target raised to $18 from $13. 100% upside. Other analysts target prices are $20 & $21.
    Bullish
  • K
    Kevin
    Easy to borrow stock, relatively cheap, got squeezed hard. remindes me on $NURO. I am expecting to be squeezed more in the premarket, then couple circuit halts and then fail follow through all day. The other scenario it will sell off at the open especially if they do offering.
  • J
    JamesA
    I asked my nephew, who has an MD and PhD and does drug development work, to look at this company. Here is his opinion: "I like this because the approach is novel and unique - so there won't be many competitors (and they own so much IP). The science is new enough to give them a lot of space to work and find one or more niches..)." So he finds Atyr's technology has promise though it was a new company for him and he didn't look into the details of their ongoing trials.
  • R
    Richard
    Two top analysts have LIFE with a $12 and $13 price target!! Whats wrong with you people, this is a GIFT!!
  • S
    Shlomo
    Strong Insider & Institutional Ownership holding 60% of the 10 M outstanding shares (chart below) / Links to Fact Sheet and Presentation below ...

    Fact Sheet
    https://investors.atyrpharma.com/static-files/a3879461-a9f6-48fc-b3c2-512a45b3259f

    Presentation
    https://investors.atyrpharma.com/static-files/eeb977f1-b798-41dc-84f4-e2844395a147

    Major Shareholders

    Federated Hermes ...1.6M
    Fidelity ...1.4M
    Alyeska ...726.0K
    Viking Global ...587.4K
    Schimmel (Paul R ...503.5K
    Altium Capital ...475.0K
    Renaissance ...365.8K
    The Vanguard ...221.9K
    Two Sigma ...213.1K
    Polaris Venture ...130.6K
    Bullish
Advertisement
Advertisement